002020 Zhejiang Jingxin Pharmaceutical
- 12.65
- -0.17-1.33%
Zhejiang Jingxin Pharmaceutical News
Zhejiang Jingxin Pharmaceutical (002020.SZ): The Phase II clinical trial of Kangfu Xinchangrong Capsules is currently in its final stages.
On December 3, Gelonghui reported that Zhejiang Jingxin Pharmaceutical (002020.SZ) stated on the investor interaction platform that the Phase II clinical trial of the Rehabilitation New Enteric Capsule is nearing its conclusion, and the company will promptly advance the Phase III clinical trial of this product according to plan after completing Phase II.
Zhejiang Jingxin Pharmaceutical's Insomnia Drug Added to National Medical Insurance Catalog
Express News | Over 20 listed companies announced after hours that pharmaceuticals have been included in the new national medical insurance catalog, with multiple innovative drugs among them.
Express News | Zhejiang Jingxin Pharmaceutical: Cidofovir capsules included in the national medical insurance catalog.
zhejiang jingxin pharmaceutical (002020.SZ): The national negotiations on Detasini capsules have been completed
On November 27, Gelonghui reported that zhejiang jingxin pharmaceutical (002020.SZ) stated on the investor interaction platform that the negotiations for the Didasine capsules have been completed. The company will announce according to the requirements of the information disclosure rules once the negotiation results are published.
Zhejiang Jingxin Pharmaceutical (002020): Q3 performance meets expectations, continuous manifestation of marketing reform results.
Event: The company released the third quarter report of 2024. In the first three quarters of 2024, the company achieved revenue of 3.209 billion yuan (+9.68% YoY) and net income attributable to the parent of 0.575 billion yuan (+21.66% YoY), after deduction.
Jingxin Pharmaceutical: Report for the third quarter of 2024
Zhejiang Jingxin Pharmaceutical (002020.SZ): The net income for the first three quarters was 0.575 billion yuan, a year-on-year increase of 21.66%.
Galaxy Securities reported on October 24 that Zhejiang Jingxin Pharmaceutical (002020.SZ) released its third-quarter report. The company achieved revenue of 3.209 billion yuan in the first three quarters, a year-on-year increase of 9.68%; net income attributable to the shareholders of the listed company was 0.575 billion yuan, a year-on-year increase of 21.66%; net income after deducting non-recurring gains and losses was 0.494 billion yuan, a year-on-year increase of 13.16%; basic earnings per share was 0.67 yuan per share.
Zhejiang Jingxin Pharmaceutical (002020.SZ) released its performance for the first three quarters, with a net income of 0.575 billion yuan, a year-on-year increase of 21.66%.
Zhejiang Jingxin Pharmaceutical (002020.SZ) released the third quarter report for 2024. In the first three quarters, the company achieved revenue...
Zhejiang Jingxin Pharmaceutical (002020.SZ): Currently able to prescribe at kn hospital in Ningbo City.
GeLonghui October 22nd | Zhejiang Jingxin Pharmaceutical (002020.SZ) stated on the investor interaction platform that KN Hospital in Ningbo can currently prescribe medication.
Guotou Securities: Guotan enters a normal stage, long-term volume can be expected for innovative drugs.
The medical insurance negotiation for 2024 is expected to start soon, with multiple domestic innovative drugs participating in this year's medical insurance negotiation.
Express News | A-share restricted shares to be lifted at a glance: 20.255 billion yuan of restricted shares in market cap will be lifted today.
Zhejiang Jingxin Pharmaceutical (002020.SZ): 67.5676 million restricted shares will be listed for trading from September 11th.
Zhejiang Jingxin Pharmaceutical (002020.SZ) issued a notification regarding the listing and circulation of privately placed restricted shares in 2020.
Zhejiang Jingxin Pharmaceutical (002020) company brief report: steady performance growth, continuous promotion of innovative drug commercialization.
Event: The company has released its 2024 interim report, achieving revenue of 2.15 billion yuan (+11.02%) and net income attributable to shareholders of listed companies of 0.402 billion yuan (+27.28%), after deducting non-recurring items, attributable to listed
Zhejiang Jingxin Pharmaceutical (002020): Steady Growth in Performance, Achievements of Business Reform Have Been Seen.
The performance is steadily improving, and the profitability continues to rise. The company released its 2024 interim report, with both revenue and net income achieving double-digit growth. In the first half of 2024, the company achieved revenue of 2.15 billion yuan (a year-on-year increase of +11.02%).
Zhejiang Jingxin Pharmaceutical (002020.SZ): JX11502MA capsules and Kangfu Xin enteric capsules II clinical trials are underway.
On August16th, www.glinfo.com reported that on August 15th, 2024, Zhejiang Jingxin Pharmaceutical (002020.SZ) stated during a specific object investigation that clinical trials of JX11502MA capsules and KefuXin enteric-coated capsules II are underway; JX2105 capsules have received clinical trial approvals, and Phase I clinical trials are progressing smoothly; more than 10 other research projects are being carried out in an orderly manner.
Zhejiang Jingxin Pharmaceutical (002020.SZ): The company's sales expenses in the first half of the year were 0.384 billion, a year-on-year decrease of 3.63%.
On August 15, 2024, during a specific research conducted by certain parties, Zhejiang Jingxin Pharmaceutical (002020.SZ) reported a sales expense of 0.384 billion, a 3.63% YoY decrease, and a 2.72 percentage point decrease in sales expense ratio. The company has achieved a continuous reduction in sales expenses in recent years, partly due to the company's emphasis on improving sales productivity, and partly due to the adjustment of the internal structure of the sales expenses and the accurate investment in cost control. With the market promotion of Daltasone, some additional expenses are inevitable, but the company will strive to control the sales expense ratio in the hope of keeping it low.
Zhejiang Jingxin Pharmaceutical (002020): Steady growth in performance, initial results of marketing reform are showing.
Event: The company released its 2024 interim report. In the first half of 2024, Zhejiang Jingxin Pharmaceutical achieved revenue of 2.15 billion (+11.02%) and net income attributable to the parent company of 0.402 billion (+27.28%), with non-net income attributable to the parent company of 3, and net income of 0.402 billion (+27.28%).
Express News | Zhejiang Jingxin Pharmaceutical: The hospitalization rhythm of Daratumumab is in line with expectations, with a planned sales of over 40 million yuan this year.
Zhejiang Jingxin Pharmaceutical (002020): Q2 performance exceeds expectations, and the finished drug market continues to exert efforts outside the hospital.
Event: The company released its 2024 interim report. In H1 2024, the company achieved revenue of 2.15 billion yuan, an increase of 11.02% year-on-year. Net income attributable to the parent was 0.402 billion yuan, an increase of 27.28% year-on-year.
Analysis
Price Target
No Data
No Data